Recombinant Biotinylated Human BTLA (31-134) Protein, Fc,Avitag™, 25 µg

Background
B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Source
Recombinant Biotinylated Human BTLA (31-134), Fc,Avitag (BTA-H82F8) is expressed from human 293 cells (HEK293). It contains AA Lys 31 - Thr 134 (Accession # Q7Z6A9).
Predicted N-terminus: Lys 31

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 40.5 kDa. The protein migrates as 48-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "Viewing the immune checkpoint VISTA: landscape and outcomes across cancers
Nishizaki, Kurzrock, Miyashita et al
ESMO Open (2024) 9 (4), 102942
(2) "Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses
van Eijck, El Haddaoui, Kucukcelebi et al
Clin Cancer Res (2024)
(3)  "The role of the BTLA-HVEM complex in the pathogenesis of breast cancer
Hu
Breast Cancer (2024)
Showing 1-3 of 688 papers.